Canadian Respiratory Journal / 2017 / Article / Tab 1

Research Article

Impaired Hemorheology in Exacerbations of COPD

Table 1

Laboratory data of the groups.

ParameterControl group
( = 12)
Newly diagnosed patient groupExacerbation group
( = 16)
Before treatment
( = 13)
After treatment
( = 13)

Hb (g/dl)15.24 ± 1.7515.54 ± 1.8215.28 ± 1.5113.57 ± 2.2 0.0520.033
Hct (%)44.95 ± 5.4247.45 ± 6.1745.78 ± 3.8840.93 ± 6.3 0.0130.045
RBC (m/µL)5.06 ± 0.615.21 ± 0.745.05 ± 0.554.57 ± 0.820.1490.106
MCV (fL)88.96 ± 3.7391.41 ± 6.5791.08 ± 5.8190.13 ± 6.650.6070.804
MCH (pg)30.17 ± 0.9729.98 ± 2.3530.34 ± 2.0729.83 ± 2.090.9050.753
MCHC (g/dl)33.95 ± 0.7932.80 ± 1.0733.32 ± 1.3233.13 ± 1.410.0600.246
WBC (K/uL)7.41 ± 1.538.33 ± 1.858.66 ± 1.809.88 ± 5.400.2280.231
Plt (K/uL)214.64 ± 31.34242.69 ± 49.77242.38 ± 35.62274.19 ± 154.620.2630.175
Fibrinogen (mg/dL)321.18 ± 115.24312 ± 86.57292.27 ± 74.51446.44 ± 193.6 0.0140.005
RDW (%)12.81 ± 0.7713.99 ± 1.2313.93 ± 1.3415.18 ± 1.6 0.0010.0001

Values are expressed as means ± SD (Hb: hemoglobin, Hct: hematocrit, RBC: red blood cell, MCV: mean corpuscular volume, MCH: mean corpuscular hemoglobin, MCHC: mean corpuscular hemoglobin concentration, WBC: white blood cell, Plt: platelet count, and RDW: red blood cell distribution width). : difference between the control group, before treatment of newly diagnosed COPD, and the exacerbation group; : difference between the control group, after treatment of newly diagnosed COPD, and the exacerbation group; < 0.05: difference from control, < 0.05: difference from before treatment of COPD, and < 0.05: difference from after treatment of COPD.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.